Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, shared a post on X:
“A new report from a military medical center in Beijing demonstrates a benefit with daily (QDay) lung SBRT schedules, particularly for stage I NSCLC tumors with high SUV values. Full disclosure: I can’t remember the last time I prescribed lung SBRT as QOD.”
Title: Pretreatment SUVmax Stratifies the Benefit of Consecutive Daily SBRT in Early-Stage Non-Small Cell Lung Cancer
Authors: Yupeng Di, Haifeng Pang, Xuan Wang, Lingling Meng
Read the Full Article.
Other articles featuring Drew Moghanaki on OncoDaily.
